Pfizer's COVID Pill <br />Protects Against Omicron Variant, New Study Finds.<br />The results of the study of the effectiveness of Pfizer's Paxlovid pill were released on Dec. 14.<br />We are confident that, if authorized or approved, this potential treatment could be a critical tool to help quell <br />the pandemic, Albert Bourla, Pfizer’s Chief Executive, <br />via 'The New York Times'.<br />The study was conducted <br />with more than two thousand <br />unvaccinated volunteers.<br />The volunteers were considered high risk for severe COVID disease.<br />The study found that when Paxlovid was given to patients within three days of the initial signs of illness.<br />the risk of both death <br />and hospitalization was <br />reduced by 89 percent.<br />If given within <br />five days of initial <br />signs of illness.<br />the risk of both death <br />and hospitalization <br />was reduced <br />by 82 percent.<br />Data from the study show that only 0.7 percent of people who received the antiviral pill needed to be hospitalized within 28 days.<br />Of those who received a placebo, 6.5 percent needed to be hospitalized or died from the disease.<br />None of the patients who received Paxlovid died from the disease.<br />Pfizer scientists expected Paxlovid's effectiveness to be much lower than the results of the study indicate.<br />We really hit the top of the board, Dr. Mikael Dolsten, Pfizer's Chief Scientific Officer, via 'The New York Times'.<br />Financial estimates regarding Paxlovid indicate that Pfizer is expected to generate at least <br />$24 billion next year
